Get the Stockscreener App
1,220.28
0.43%
5.26
After Hours:
1221.29
1.01
+0.08%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,220.28, with a volume of 1.94M.
It is up +0.43% in the last 24 hours and up +2.67% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,215.02
Open:
$1201.73
24h Volume:
1.94M
Relative Volume:
0.65
Market Cap:
$1.09T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
43.92
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+4.31%
1M Performance:
+2.67%
6M Performance:
+17.53%
1Y Performance:
+90.84%
1-Day Range:
$1,191.08
$1,226.50
1-Week Range:
$1,161.20
$1,238.00
52-Week Range:
$644.50
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,220.28 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.86 | 626.09B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.76 | 441.94B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
132.92 | 321.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.32 | 293.87B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales - RTTNews
Is Eli Lilly (NYSE:LLY) Drawing Fresh Attention As Incretin Therapies Advance? - kalkinemedia.com
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly By Investing.com - Investing.com India
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly - Investing.com
What Is Keeping Eli Lilly (NYSE:LLY) in View as Inflation Data Nears? - kalkinemedia.com
‘Entirely Unverified Retatrutide’ Being Sold on Black Market: Lilly Sues 6 US Companies - Health and Me
Lilly Targets Black-Market Retatrutide Sellers - TradingView
Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug - Straight Arrow
Veeva Systems (VEEV) Expands AI CRM Role With Eli Lilly Win Is Its Moat Deepening? - simplywall.st
Eli Lilly files first lawsuits over retatrutide ‘black market’ - Endpoints News
Lilly escalates fight over weight-loss shots sold on black market - Indianapolis Business Journal
Eli Lilly Goes After Sellers of Its Unapproved Drug - newser.com
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug - The Hill
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade) (LLY) - Seeking Alpha
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas - Fierce Pharma
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities - Benzinga
Lilly escalates its fight against black market weight-loss shots - fortune.com
Lilly Escalates Its Fight Against Black Market Weight-Loss Shots - Bloomberg.com
Lilly Escalates Fight Against Black Market Weight-Loss Shots (3) - Bloomberg Law News
Eli Lilly Sues 6 US Sellers Over Black-Market Retatrutide, Calls Products ‘Unverified’ - outlookbusiness.com
InduPro's 'protein neighbourhoods' draw Sanofi, Lilly backing after earlier deals - FirstWord Pharma
Lilly sues six U.S. companies for allegedly selling black-market retatrutide - PharmaLive
Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup - ChartMill
Lilly cracks down on retatrutide black marketeers - FirstWord Pharma
Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’ - TradingView
Black-Market GLP-1s: Eli Lilly Sues Six Sellers Of Experimental Obesity Drugs - NDTV Profit
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs - WSJ
Eli Lilly Sues Six US Companies Over Illegal Retatrutide Sales - mezha.net
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug - qz.com
Tema ETFs LLC Has $29.99 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Eli Lilly escalates fight against black market weight-loss medicines - BusinessLine
Berenberg cuts Novo Nordisk as Lilly’s obesity dominance limits upside By Investing.com - Investing.com Australia
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market - PR Newswire
Eli Lilly official, others explain what brought their companies to Alabama - Decatur Daily
Better Buy: Eli Lilly vs. Novo Nordisk - fool.com
Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Down 1.5% After Insider Selling - MarketBeat
Eli Lilly's Weight-Loss Pill Wins U.K. Approval - Briefs Finance
Why Is Eli Lilly (NYSE:LLY) the Healthcare Name in Focus After Its Obesity Pill Nod? - Kalkine Media
Eli Lilly Scores Major Win in Weight-Loss Drug Race - finance.yahoo.com
Eli Lilly Just Made a Huge Bet on Psychedelics for Mental Health - Flow Space
Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles - Investing News Network
Eli Lilly (NYSE:LLY) Oncology Push Opens A Bigger Story - Kalkine Media
Lilly's Foundayo Pill Lands First European Approval, Challenging Novo's Wegovy in UK - finance.biggo.com
Lilly Takes Its Weight-Loss Pill Battle Overseas - GuruFocus
ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com - Investing.com South Africa
MedPal AI eyes private GLP-1 market after UK authorises Eli Lilly weight-loss pill - Yahoo Finance UK
Eli Lilly commits to Veeva Vault CRM globally By Investing.com - Investing.com Canada
UK first in Europe to approve Eli Lilly oral weight loss drug - The Economic Times
Eli Lilly commits to Veeva Vault CRM globally - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):